keyword
MENU ▼
Read by QxMD icon Read
search

ASCO

keyword
https://www.readbyqxmd.com/read/28631735/in-the-news-from-asco-2017
#1
David Killock
No abstract text is available yet for this article.
June 20, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28618241/use-of-adjuvant-bisphosphonates-and-other-bone-modifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline
#2
Sukhbinder Dhesy-Thind, Glenn G Fletcher, Phillip S Blanchette, Mark J Clemons, Melissa S Dillmon, Elizabeth S Frank, Sonal Gandhi, Rasna Gupta, Mihaela Mates, Beverly Moy, Ted Vandenberg, Catherine H Van Poznak
Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer. Methods Cancer Care Ontario and ASCO convened a Working Group and Expert Panel to develop evidence-based recommendations informed by a systematic review of the literature. Results Adjuvant bisphosphonates were found to reduce bone recurrence and improve survival in postmenopausal patients with nonmetastatic breast cancer. In this guideline, postmenopausal includes patients with natural menopause or that induced by ovarian suppression or ablation...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28617618/value-based-calculators-in-cancer-current-state-and-challenges
#3
Chadi Nabhan, Bruce A Feinberg
The ASCO Value Framework, National Comprehensive Cancer Network Evidence Blocks, Memorial Sloan Kettering's DrugAbacus, and Institute for Clinical and Economic Review incremental cost-effectiveness ratio calculator are value-based methodologies that attempt to address the disproportionate increase in cancer care spending. These calculators can be used as an initial step for discussing cost versus value, but they fall short in recognizing the importance of the cancer journey because they do not fully factor the patient's perspective or the global cost of care...
June 15, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28616930/-a-study-of-etiology-classification-of-minor-stroke-based-on-toast-and-asco-systems
#4
Jie Zhou, Yang Zhang, Yi-Jia Guo, Li He
OBJECTIVES: To investigate the differences in the etiology between minor stroke and non-minor stroke based on TOAST and ASCO systems, and to guide the early intervention for minor stroke. METHODS: We retrospectively analyzed the patients with acute ischemic stroke admitted to our department from July 2012 to July 2014. We sub-typed minor stroke patients and non-minor stroke patients in etiology using Trial of Org 10172 in Acute Stroke Treatment (TOAST) and ASCO (A for atherosclerosis, S for small vessel disease, C for Cardiac source, O for other cause) systems respectively to investigate the difference of etiology between the two groups...
May 2017: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/28616122/new-research-in-testicular-cancer-asco-gu-2017
#5
REVIEW
Robert J Hamilton, Christian Kollmansberger
No abstract text is available yet for this article.
June 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28616121/new-research-in-prostate-cancer-asco-gu-2017
#6
REVIEW
Kim Chi, Fred Saad
No abstract text is available yet for this article.
June 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28616120/new-research-in-kidney-cancer-asco-gu-2017
#7
REVIEW
Naveen Basappa, Frederic Pouliot
No abstract text is available yet for this article.
June 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28616119/new-research-in-bladder-cancer-asco-gu-2017
#8
REVIEW
Peter C Black, Srikala Sridhar
No abstract text is available yet for this article.
June 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28602776/2017-asco-annual-meeting
#9
Farhat Yaqub
No abstract text is available yet for this article.
June 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28596016/multi-disciplinary-summit-on-genetics-services-for-women-with-gynecologic-cancers-a-society-of-gynecologic-oncology-white-paper
#10
Leslie M Randall, Bhavana Pothuri, Elizabeth M Swisher, John P Diaz, Adam Buchanan, Catherine T Witkop, C Bethan Powell, Ellen Blair Smith, Mark E Robson, Jeff Boyd, Robert L Coleman, Karen Lu
OBJECTIVE: To assess current practice, advise minimum standards, and identify educational gaps relevant to genetic screening, counseling, and testing of women affected by gynecologic cancers. METHODS: The Society of Gynecologic Oncology (SGO) organized a multidisciplinary summit that included representatives from the American College of Obstetricians and Gynecologists (ACOG), the American Society Clinical Oncology (ASCO), the National Society of Genetic Counselors (NSGC), and patient advocacy groups, BrightPink and Facing our Risk of Cancer Empowered (FORCE)...
June 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28589728/spectroscopic-characterization-computational-investigation-and-comparisons-of-ecx-e-as-p-and-n-x-s-and-o-anions
#11
Gao-Lei Hou, Bo Chen, Wesley J Transue, Zheng Yang, Hansjörg Grützmacher, Matthias Driess, Christopher C Cummins, Weston Thatcher Borden, Xue-Bin Wang
Three newly synthesized [Na(+)(221-Kryptofix)] salts containing AsCO(-), PCO(-), and PCS(-) anions were successfully electrosprayed into a vacuum, and these three ECX(-) anions were investigated by negative ion photoelectron spectroscopy (NIPES) along with high-resolution photoelectron imaging spectroscopy. For each ECX(-) anion, a well-resolved NIPE spectrum was obtained, in which every major peak is split into a doublet. The splittings are attributed to spin-orbit coupling (SOC) in the ECX(•) radicals. Vibrational progressions in the NIPE spectra of ECX(-) were assigned to the symmetric and the antisymmetric stretching modes in ECX(•) radicals...
June 23, 2017: Journal of the American Chemical Society
https://www.readbyqxmd.com/read/28586259/implementation-of-advance-care-planning-in-oncology-a-review-of-the-literature
#12
Christine M Bestvina, Blase N Polite
Advance care planning (ACP) should be initiated early and be readdressed often for patients with cancer. This directive is expressed in the Institute of Medicine's report, "Dying in America," and is a component of several quality metrics, including ASCO's Quality Oncology Practice Initiative and the Centers for Medicare & Medicaid Services Oncology Care Model. Although simple in concept, implementation in practice is challenging. A variety of patient education tools exist in several different forms, including pamphlets, guidebooks, and question prompt lists, with the strongest data supporting the use of video decision aids that depict cardiopulmonary resuscitation...
June 6, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28583794/delivery-of-meaningful-cancer-care-a-retrospective-cohort-study-assessing-cost-and-benefit-with-the-asco-and-esmo-frameworks
#13
Joseph C Del Paggio, Richard Sullivan, Deborah Schrag, Wilma M Hopman, Biju Azariah, C S Pramesh, Ian F Tannock, Christopher M Booth
BACKGROUND: The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have developed frameworks that quantify survival gains in light of toxicity and quality of life to assess the benefits of cancer therapies. We applied these frameworks to a cohort of contemporary randomised controlled trials to explore agreement between the two approaches and to assess the relation between treatment benefit and cost. METHODS: We identified all randomised controlled trials of systemic therapies in non-small-cell lung cancer, breast cancer, colorectal cancer, and pancreatic cancer published between Jan 1, 2011, and Dec 31, 2015, and assessed their abstracts and methods...
June 2, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28576857/braf-mutations-as-predictive-biomarker-for-response-to-anti-egfr-monoclonal-antibodies
#14
Emilie M J van Brummelen, Anthonius de Boer, Jos H Beijnen, Jan H M Schellens
Recently, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommended that patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer could be treated with anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab only in absence of Rat-Sarcoma (RAS) mutations. In addition to the previously established biomarker Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, cumulative evidence also shows that patients whose tumors harbor KRAS exons 3 or 4 and neuroblastoma rat-sarcoma viral oncogene homolog (NRAS) exons 2, 3, and 4 mutations are found unlikely to benefit from anti-EGFR treatment...
June 2, 2017: Oncologist
https://www.readbyqxmd.com/read/28575861/diagnostic-accuracy-of-pcr-for-detecting-alk-gene-rearrangement-in-nsclc-patients-a-systematic-review-and-meta-analysis
#15
Xia Zhang, Jian-Guo Zhou, Hua-Lian Wu, Hu Ma, Zhi-Xia Jiang
BACKGROUND: Anaplastic lymphoma kinase (ALK) gene fusion has been reported in 3~5% non-small cell lung carcinoma (NSCLC) patients, and polymerase chain reaction (PCR) is commonly used to detecting the gene status, but the diagnostic capacity of it is still controversial. A systematic review and meta-analysis was conducted to clarify the diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients. RESULTS: 18 articles were enrolled, which included 21 studies, involving 2800 samples from NSCLC patients...
May 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28574778/do-the-american-society-of-clinical-oncology-value-framework-and-the-european-society-of-medical-oncology-magnitude-of-clinical-benefit-scale-measure-the-same-construct-of-clinical-benefit
#16
Sierra Cheng, Erica J McDonald, Matthew C Cheung, Vanessa S Arciero, Mahin Qureshi, Di Jiang, Doreen Ezeife, Mona Sabharwal, Alexandra Chambers, Dolly Han, Natasha Leighl, Kelley-Anne Sabarre, Kelvin K W Chan
Purpose Whether the ASCO Value Framework and the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale (MCBS) measure similar constructs of clinical benefit is unclear. It is also unclear how they relate to quality-adjusted life-years (QALYs) and funding recommendations in the United Kingdom and Canada. Methods Randomized clinical trials of oncology drug approvals by the US Food and Drug Administration, European Medicines Agency, and Health Canada between 2006 and August 2015 were identified and scored using the ASCO version 1 (v1) framework, ASCO version 2 (v2) framework, and ESMO-MCBS by at least two independent reviewers...
June 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28561724/strategies-to-maximize-patient-participation-in-clinical-trials
#17
Eric H Rubin, Mary J Scroggins, Kirsten B Goldberg, Julia A Beaver
Despite considerable interest and success in oncology drug development, the minority of patients with cancer diagnoses enroll in clinical trials. Multiple obstacles account for this low enrollment rate. An improvement in patient participation in clinical trials could increase patient access to novel and potentially promising agents, provide faster trial results, and, with implementation of rational eligibility criteria, allow for a better understanding of the drug's safety and efficacy in a heterogeneous population...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28561709/practice-model-for-advanced-practice-providers-in-oncology
#18
Jamie Cairo, Mary Ann Muzi, Deanna Ficke, Shaunta Ford-Pierce, Katrina Goetzke, Diane Stumvoll, Laurie Williams, Federico A Sanchez
According to ASCO, the number of practicing oncologists has remained stable despite growth demands, leading to an overall shortage in many areas of the country. Nurse practitioners and physician assistants are advanced practice providers (APPs) who can assist in the provision of support and care to patients with cancer, but the role of the APP in the oncology setting has not been well defined. There exists a variety of different practice patterns for APPs who work in oncology, and the lack of role definition and absence of an established practice model are considered leading causes of APP attrition...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28561702/perspectives-on-the-use-of-clinical-pathways-in-oncology-care
#19
Anne C Chiang, Peter Ellis, Robin Zon
Pathways and guidelines are valuable tools to provide evidence-based care in oncology. Pathways may be more restrictive than guidelines because they attempt (where possible) to reduce cost, add efficiency, and remove unwarranted variability. Pathways offer an opportunity to measure, report, and improve quality of care; they can drive to evidence-based targeted therapy where appropriate; they can enhance efficiency through standardization; and, finally, they can be a vehicle to enhance participation in clinical trials...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28561696/using-the-new-asco-clinical-practice-guideline-for-palliative-care-concurrent-with-oncology-care-using-the-team-approach
#20
Cardinale B Smith, Tanyanika Phillips, Thomas J Smith
Palliative care alongside usual oncology care is now recommended by ASCO as the standard of care for any patient with advanced cancer on the basis of multiple randomized trials that show better results with concurrent care than with usual oncology care. Some benefits include better quality of life, better symptom management, reduced anxiety and depression, less caregiver distress, more accordance of care with the wishes of the patient, and less aggressive end-of-life care. Several studies show a survival advantage of several months, and many show considerable cost savings: better care at an affordable cost...
2017: American Society of Clinical Oncology Educational Book
keyword
keyword
33466
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"